Browse Articles

Discover research articles across all indexed journals

Total neoadjuvant therapy followed by total mesorectal excision and selective lateral lymph node dissection for locoregionally advanced low rectal cancer: A phase III randomized controlled trial (JCOG2207).

Journal of Clinical Oncology Masayoshi Yasui, Masayuki Ohue, Senzo Taguchi et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.tps312

TPS312 Background: For locally advanced low rectal cancer (RC), total neoadjuvant therapy (TNT) followed by total mesorectal excision (TME) confers a survival advantage compared with neoadjuvant chemoradiotherapy (nCRT) in the West, even though the local control rate was similar between TNT and nCRT. The Japan Clinical Oncology Group (JCOG) Colorectal Cancer Study Group has been developing therapies for RC based on recurrence risk according to presence/absence of clinical lateral lymph node metastasis (cLLNM). Our previous study in Japan showed that the standard of care (SOC) for RC is TME with lateral lymph node dissection (LLND) plus adjuvant chemotherapy (CTx). However, the prognosis for cStage III low RC remains poor regardless of cLLNM status. Therefore, new treatment strategies are needed for this population. In cLLNM-positive cStage III low RC patients, previous research suggests that adding nCRT to LLND would reduce local recurrence and improve survival. TNT and LLND may further improve outcomes. In cLLNM-negative cStage III low RC, several reports have suggested that nCRT as an alternative addition to LLND has comparable efficacy in terms of local control. Thus, in these populations, if TNT can replace LLND, adverse events due to LLND can be avoided while improving prognosis. We hypothesize that TNT + TME + selective LLND would be the most promising strategy for cLLNM-positive and -negative cStage III low RC. Methods: Eligibility criteria include low rectal adenocarcinoma or adenosquamous carcinoma, cT2-cT4 tumor depth, clinically positive lymph node metastasis, no distant metastasis, no history of pelvic irradiation or rectal surgery, age 18-75 years, and sufficient organ function. Eligible patients are randomized (1:1) with adjustment factors of institution, sex, and cLLNM status. The experimental treatment arm receives TNT, short-course radiotherapy (25 Gy/5 fractions to whole pelvis), and consolidation chemotherapy consisting of 6 courses of CAPOX (oxaliplatin 130 mg/m2 on day 1 and capecitabine 2000 mg/m2/day on days 1-14). After completing TNT, TME + selective LLND are performed for cLLNM-positive cases or TME alone for cLLNM-negative cases. The SOC arm receives TME + LLND followed by adjuvant chemotherapy with 8 cycles of CAPOX (same as above). The primary endpoint is overall survival (OS) in the intention-to-treat population. To detect an increase in 5-year OS from 76% to 84%, corresponding to a target hazard ratio of 0.64, 408 patients (108 events) would achieve 75% power at a one-sided α of 0.05, an expected accrual period of 4 years, and a follow-up period of 5 years. The total sample size was set at 420 patients to account for patients lost to follow-up. Accrual in JCOG2207 began in October 2023. Clinical trial information: s031230415 .

MEK inhibitor-based therapy in metastatic pancreatic adenocarcinoma with <i>KRAS</i> G12R alteration.

Journal of Clinical Oncology Elizabeth Auckley, Grace Ying, Stephanie Yohay et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.725

725 Background: Pancreatic ductal adenocarcinoma (PDAC) is largely driven by oncogenic alterations in the KRAS , TP53 , CDKN2A/B , and SMAD4 genes. KRAS G12R accounts for nearly 20% of KRAS alterations in PDAC, is biologically unique, and offers the potential for improved response to MEK inhibitor (MEK-inh)-based therapy. As part of the MCW-Master-PREDICT (NCT05802069) observational study, we evaluated the efficacy of MEK-inh-based therapy matched to the unique molecular alterations in the tumor of each patient as recommended by the molecular tumor board. Methods: From March 2022 to December 2023, 8 patients with metastatic PDAC were treated with MEK-inh-based therapy. Molecular profiling was performed by Tempus (648 genes) in 7 patients, and FoundationOne (324 genes) in 1 patient. Description of molecular alterations, matched therapies, and efficacy of treatment are provided. Results: The median age of patients starting MEK inhibitor-based therapy was 69 years, with 62% of them being female. The molecular characteristics and matched therapies are summarized (Table). MEK-inh-based therapy was administered to 3 (37.5%) patients as a first or second-line treatment, and to 5 (62.5%) patients as a third to fifth-line treatment for metastatic PDAC. The overall survival and progression free survival (PFS) on MEK-inh-based therapy was 8.4 and 4.9 months, respectively. Four patients had PFS beyond 4 months (4.9, 5.5, 5.6 and 6.9 months). Conclusions: Individualized MEK-inh-based therapy demonstrated efficacy in late-line treatment of metastatic PDAC with KRAS G12R alterations. Using this approach earlier in the treatment course and in combination with RAS inhibitors or cytotoxic systemic therapies may further enhance outcomes. Tumor alterations and matched therapies. Gene altered Number of patients (%) Number of patients matched (%) Drug family matched KRAS G12R 8 (100) 8/8 (100) MEK inhibitor TP53 7 (87.5) 4/7 (57) VEGF/VEGR inhibitor* CDKN2A 4 (50) 4/4 (100) CDK4/6 inhibitor** SMAD4 2 (25) 2/2 (100) MEK inhibitor + (EGFR or Pan-HER inhibitor)*** *PMID: 27466356; **PMID: 33472910; ***PMID: 36127339, PMID: 24625091.

Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies

Nature Communications Yan-Ruide Li, Ying Fang, Siyue Niu et al. Feb 01, 2025 DOI: 10.1038/s41467-025-56270-6

Abstract Chimeric antigen receptor (CAR)-engineered T cell therapy holds promise for treating myeloid malignancies, but challenges remain in bone marrow (BM) infiltration and targeting BM-resident malignant cells. Current autologous CAR-T therapies also face manufacturing and patient selection issues, underscoring the need for off-the-shelf products. In this study, we characterize primary patient samples and identify a unique therapeutic opportunity for CAR-engineered invariant natural killer T (CAR-NKT) cells. Using stem cell gene engineering and a clinically guided culture method, we generate allogeneic CD33-directed CAR-NKT cells with high yield, purity, and robustness. In preclinical mouse models, CAR-NKT cells exhibit strong BM homing and effectively target BM-resident malignant blast cells, including CD33-low/negative leukemia stem and progenitor cells. Furthermore, CAR-NKT cells synergize with hypomethylating agents, enhancing tumor-killing efficacy. These cells also show minimal off-tumor toxicity, reduced graft-versus-host disease and cytokine release syndrome risks, and resistance to allorejection, highlighting their substantial therapeutic potential for treating myeloid malignancies.

Toward Fast‐Charging and Dendritic‐Free Li Growth on Natural Graphite Through Intercalation/Conversion on MoS <sub>2</sub> Nanosheets

Advanced Materials Joo Hyeong Suh, Sang A Han, Soo Young Yang et al. Feb 01, 2025 DOI: 10.1002/adma.202414117

Abstract During fast‐charging, uneven lithium plating on the surface of commercial graphite anode impedes the electrochemical performance of lithium‐ion batteries, causing a safety issue. The formation of a passivation layer, the solid‐electrolyte interphase (SEI), due to side reactions with the organic electrolyte, correlates with long‐term cycling performance under fast‐charging conditions, necessitating comprehensive analysis. Herein, it is demonstrated that a molybdenum disulfide (MoS 2 ) coating on natural graphite (NG) modulates the properties of the SEI layer, enabling reduction of the charging time and the enhancement of long‐term cycling performance. MoS 2 spontaneously transforms into Li 2 S and Mo nanoclusters through intercalation and conversion with Li + , altering the chemical composition and stability of the SEI layer on the NG, promoting faster Li + transport, and reducing interfacial resistance. The MoS 2 ‐NG anode shows improved fast‐charging capability and cycling performance under 3.0 C‐charging and 1.0 C‐discharging over 300 cycles without compromising energy density. In the full‐cell configuration, a charging time of 14.7 min at 80% state of charge is achieved, making it suitable for electric vehicle applications.

Updated results of ALTER-H006: A phase II study of benmelstobart (PD-L1 inhibitor) plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after radical resection.

Journal of Clinical Oncology Xianhai Ma0, Xiaohui Duan, Dongde Wu et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.601

601 Background: Although radical resection offers one of the most favorable prognosis for hepatocellular carcinoma (HCC), the rate of postoperative recurrence remains high, which is the primary cause of mortality in HCC patients. The optimal adjuvant treatment strategy for patients is still under active investigation. Herein we evaluated the efficacy and safety of the anti-angiogenic tyrosine kinase inhibitor, anlotinib, plus benmelstobart, a novel programmed death-ligand 1 (PD-L1) inhibitor as an adjuvant treatment for HCC with high risk of recurrence after radical resection. Methods: This study enrolled patients diagnosed with HCC confirmed through histological or cytological examination, whose age was 18-75, with ECOG 0-1, Child-Pugh class A, 4~8 weeks after R0 resection with any of the following high-risk factors for recurrence: a) tumor nodules ≥4; b) portal vein tumor thrombus (PVTT): vp1 or vp2; c) hepatic vein tumor thrombus (HVTT): vv1 or vv2. Enrolled patients received anlotinib (12 mg, p.o., qd, d1-14, q3w) plus benmelstobart (1200 mg, i.v., d1, q3w) until disease recurrence or unacceptable toxicity or up to 18 cycles (~1 year), whichever occurred first. Tumor assessment was performed at the end of the second cycle and every four cycles thereafter, according to RECIST v1.1. The predefined sample size was 37. The primary endpoint was 1-year recurrence-free survival (RFS) rate. Secondary endpoints included RFS, 1-year overall survival (OS) rate, and safety. Results: As the cutoff date of September 13,2024, a total of 38 patients (pts) were enrolled and 35 pts included in per-protocol set analysis. The majority of the 38 pts were male (94.7%, n = 36), and the median age was 56.5 years (range: 33-75). 18 pts (47.3%) had CNLC Stage IIb and 20 (52.6%) had CNLC Stage IIIa HCC. Among them, 35 pts received at least once tumor assessment. According to RECIST 1.1, of the 35 pts, 18 had no recurrence, 15 experienced relapse, 1 dropped out and 1 discontinued due to serious adverse events. The 1-year RFS rate was 59.97% (95%CI: 39.12-79.68) and the primary median RFS was 16.89m(95%CI: 6.82-26.96). The 1-year OS rate was 91.47% (95%CI: 69.23-97.86). 34 of 38 pts (89.5%) experienced treatment-related adverse events (TRAEs). The most common grade 3 TRAEs occurred in 17 pts (44.7%) including hypertension (32%) and neutropenia(5.3%). No grade 4 or 5 TRAEs were observed. Conclusions: The present study indicated that anlotinib plus benmelstobart as adjuvant treatment for HCC with high risk of recurrence after radical resection exhibited promising efficacy and tolerable safety profile. The conclusion should be validated in more participants included subsequently. Clinical trial information: NCT05111366 .

Adherence to multi-target stool DNA test in the US Asian population from 2017-2024.

Journal of Clinical Oncology Mallik Greene, Mark Camardo, Quang Anh Le et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.101

101 Background: In 2024, incidence and mortality cases related to colorectal cancer (CRC) in the US are estimated to reach 152,810 and 53,010, respectively. CRC screening can help identify malignant lesions at earlier stages; however, in 2021, only 48% of Asian American persons between the ages of 45-75 were up-to-date. Multi-target stool DNA test (mt-sDNA), a highly sensitive and guideline recommended CRC screening modality, may improve screening adherence in average-risk individuals within this population. Herein, we examined CRC screening adherence with mt-sDNA in Asian Americans using national claims data. Methods: A large claims database of over 165 million individuals linked with Exact Sciences Laboratories data, was used to source mt-sDNA orders for Asian Americans from 2017 to 2024. Eligible individuals were aged ≥45 years, new to mt-sDNA and average risk for CRC during the baseline period of 12 months. Primary outcome was adherence to mt-sDNA, defined as return of mt-sDNA kit within 365-days from shipment. The secondary outcome was time to kit return in days. All individuals received a standard mailed letter along with additional digital outreach through the accompanying mt-sDNA patient navigation program, according to their desired mode of communication. Baseline demographic measures included age, sex, ordering provider, residential geography, payor, and outreach preference. Association of adherence with patient characteristics was evaluated using multivariable regression. Results: Of the 182,259 eligible mt-sDNA orders shipped during the study period, overall adherence was 68.9%. Average time to test return was 27.1 days. The cohort was comprised mostly of women (56.7%), aged 50-64 years (58.42%), primary care provider (74.7%), and preferred ‘Digital SMS’ outreach (50.9%). Average adherence for all age groups, 45-49 years, 50-64 years, 65-75 years, and 76+ years, exceeded 65%, at 67.2%, 68.8%, 69.7%, and 72%, respectively. Medicare recipients demonstrated the highest adherence by payor type (71%, p &lt; 0.0001), and persons who opted for ‘Digital SMS + Email’ communication were most adherent (70.9%; p &lt; 0.0001). Of all provider specialties, individuals having their tests ordered by gastroenterologists produced the shortest time to adherence (21.8 days). Multivariable regression revealed that age, digital outreach (compared to none), micropolitan residence, and ordering provider were independent predictors of increased mt-sDNA adherence. Conclusions: The results of this large cohort and nationally representative analysis demonstrated high mt-sDNA adherence amongst Asian American persons, despite a low percentage of this population being current with CRC screening overall. The use of mt-sDNA, in concordance with its included patient navigation, is a viable modality to encourage test completion through screening engagement – which has the potential to reduce screening barriers in this population.

Predicting mortality in upper gastrointestinal tract cancer using long short-term memory neural networks.

Journal of Clinical Oncology Manaswitha Thota, Sidharth Mahajan, Sri Harsha Boppana et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.340

340 Background: Upper gastrointestinal (GI) tract cancers represent a significant global health burden, characterized by high morbidity and mortality rates, with an increasing incidence among aging populations and varying outcomes based on gender and ethnicity. Early prediction of mortality rates in upper gastrointestinal cancer can significantly enhance treatment strategies and patient outcomes. This study describes current trends in upper gastrointestinal cancer and proposes a predictive model, developed using Long Short-Term Memory (LSTM) neural networks to project future trends using demographic data. Methods: We extracted mortality data from the Center for Disease Control and Prevention (CDC) Wide-Ranging Online Data for Epidemiological Research (WONDER) Database spanning 1999, normalized it and encoded categorical variables such as age, sex, ethnicity, and race numerically. Using Studio R to analyze mortality trends, we developed an LSTM model known for its ability to capture and utilize long term data patterns. The model, trained with a sequence length of 20, predicted future data points based on the previous 20. We then assessed its accuracy and generalization with a test set. Ultimately, our model is able to utilize demographic variables to forecast annual mortality and survival rates. Results: The mortality rates for upper GI tract cancers are notably higher among elderly individuals, particularly those aged 80 and above, with males and certain ethnic groups, such as Hispanics. The accuracy of the trained model was evaluated by calculating the Mean Squared Error (MSE), a measure of the difference between the predicted and actual value, with zero indicating no difference between the two. Our LSTM model achieved a training MSE of 0.00085 and a validation MSE of 0.0016, indicating good reliability and accuracy. Conclusions: Our analysis highlighted clear mortality trends and demonstrated the model’s effectiveness in improving mortality predictions in upper gastrointestinal cancer. However, limitations due to the dataset’s lack of clinical variables (such as comorbidities, cancer stage, and prior treatments) and its reliance on a single dataset may affect external validity. Future research is needed to determine if the model can be applied for clinical prognosis or strategic planning. We ultimately created and validated an LSTM neural network model with the CDC WONDER dataset, showing promising results. Future development will aim to include clinical characteristics to create a more personalized predictive tool.

Electrosynthesis of NH3 from NO with ampere-level current density in a pressurized electrolyzer

Nature Communications Wenqiang Yang, Huan Liu, Xiaoxia Chang et al. Feb 01, 2025 DOI: 10.1038/s41467-025-56548-9

Understanding the Dynamic Evolution of Active Sites among Single Atoms, Clusters, and Nanoparticles

Advanced Materials Hongchen Yang, Pengfei Duan, Zechao Zhuang et al. Feb 01, 2025 DOI: 10.1002/adma.202415265

Abstract Catalysis remains a cornerstone of chemical research, with the active sites of catalysts being crucial for their functionality. Identifying active sites, particularly during the reaction process, is crucial for elucidating the relationship between a catalyst's structure and its catalytic property. However, the dynamic evolution of active sites within heterogeneous metal catalysts presents a substantial challenge for accurately pinpointing the real active sites. The advent of in situ and operando characterization techniques has illuminated the path toward understanding the dynamic changes of active sites, offering robust scientific evidence to support the rational design of catalysts. There is a pressing need for a comprehensive review that systematically explores the dynamic evolution among single atoms, clusters, and nanoparticles as active sites during the reaction process, utilizing in situ and operando characterization techniques. This review aims to delineate the effects of various reaction factors on dynamic evolution of active sites among single atoms, clusters, and nanoparticles. Moreover, several in situ and operando techniques are elaborated with emphases on tracking the dynamic evolution of active sites, linking them to catalytic properties. Finally, it discusses challenges and future perspectives in identifying active sites during the reaction process and advancing in situ and operando characterization techniques.

Racial, gender and socioeconomic disparities in survival outcomes of hepatocellular carcinoma.

Journal of Clinical Oncology Oboseh John Ogedegbe, Olanipekun Lanny Ntukidem, Sakshi Bai et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.526

526 Background: Hepatocellular carcinoma (HCC) is the sixth most commonly occurring cancer worldwide, with mortality rates increasing globally, particularly in the Western world. The 5‐year survival rate of persons with HCC is less than 20%. It is, therefore, essential to investigate the extent to which social determinants of health influence survival outcomes. In this study, we explored the effect of gender, race/ethnicity and socioeconomic factors on survival outcomes among patients with HCC in the United States. Methods: We extracted data on patients with a histologic diagnosis of hepatocellular carcinoma from the Surveillance, Epidemiology and End Result (SEER) Registry from 2000-2021. The primary outcome of interest was the cause-specific survival of these patients. According to the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) system, the histological code of HCC is 8170/3. We excluded patients of missing or unknown race, income, location, and patients outside the years of study. Cox proportional hazard regression (SPSS) was utilized to determine the association between patients' race/ethnicity, gender, annual median income, location and cause-specific survival. Results: 80,445 met the criteria and were included in our study. Gender proved to be a predictor of survival; compared to females, males had worse outcomes, with males HR 1.040 (95% CI; 1.020-1.060, p = &lt;0.001). Race was a predictor of survival outcomes. Using American Indian/Alaska Native as our reference, Asian/Pacific Islander HR 0.847 (95% CI; 0.790-0.90, p = &lt;0.001), Black HR 1.019 (95% CI; 0.950-1.093, p = 0.603), White HR 0.955 (95% CI; 0.893-1.023, p = 0.186). We also analyzed the effects of socioeconomic factors on survival. Patients with higher annual median income had better outcomes. &gt;$120000 HR 0.817 (95% CI; 0.783-0.851, p = &lt;0.001) while patients with lower annual median income had worse outcomes &lt; $40000 HR 1.217 (95% CI; 1.134-1.305, p &lt; 0.001). The effect of location on survival was not significant. Compared to non-metropolitan areas, metropolitan areas HR 0.988 (95% CI; 0.971–1.004, p = 0.138). Conclusions: Race/ethnicity, income and gender disparities all played a significant role in cause-specific survival in patients with HCC, with improved survival observed in females, Asians and patients with higher annual median income. More efforts are needed to bridge these survival disparities.

Development of a methylation-based, tissue-agnostic test for the detection of molecular residual disease by circulating tumor DNA.

Journal of Clinical Oncology John Paul Y.C. Shen, Johannes Reiter, Joshua Babiarz et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.266

266 Background: Clinical validation studies support tumor-informed molecular residual disease (MRD) as a prognostic biomarker for disease recurrence across multiple solid tumor types. However, these tests are not always feasible due to the occasional lack of tumor tissue. Here, we discuss the design of a test for tissue-agnostic MRD detection and its application to a cohort of patients with colorectal cancer (CRC). Methods: A targeted panel composed of differentially methylated regions was developed. A machine-learning model was trained on differential methylation patterns in order to classify plasma samples as MRD-positive or MRD-negative. Performance of the independently trained classifier was assessed in a cohort of 247 patients enrolled in the Bespoke CRC trial (NCT04264702). These patients had MRD results available using a tumor-informed circulating tumor DNA (ctDNA) assay (Signatera), of whom 163 were persistently MRD-negative without clinical progression and 84 had MRD-positive results. Tissue-agnostic MRD results were compared to the tumor-informed results by calculating the percent positive agreement (PPA). Additionally, the differentially methylated allele fraction (DMAF) from the tissue-agnostic test was compared with variant allele frequencies (VAFs) from the tumor-informed test. Results: In the Bespoke CRC clinical cohort (72% non-Hispanic White, 54% male, mean age 61.4±12.3 years), 71 (28%) patients had stage II CRC, and 147 (60%) had stage III CRC. Overall, PPA was 86% (95% CI: 70-100%) and specificity was 97% (95% CI: 93-100%). When categorizing based on tumor-informed MRD VAF levels, PPA was 97% for VAF &gt;0.2%, 100% for VAF 0.1-0.2%, 89% for VAF 0.04-0.1%, and 68% for VAF &lt;0.04%. The DMAFs strongly correlated with the VAFs from the tumor-informed test and the correlation was independent of disease stage, histology, age, and sex. Conclusions: This is the first study of its kind demonstrating high concordance between a tissue-agnostic MRD test and a clinically validated tumor-informed ctDNA assay. These findings demonstrate that in cases where tissue is not available or of inadequate quality, a methylation-based tissue-agnostic assay may serve as a potential alternative for MRD detection.

Pembrolizumab or placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: An updated analysis of KEYNOTE-859 for patients enrolled in Asia.

Journal of Clinical Oncology Chia Jui Yen, Do-Youn Oh, Yuxian Bai et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.464

464 Background: After a median follow-up of 41.6 months, data from the global phase 3 KEYNOTE-859 study (NCT03675737; N = 1579) continued to show that use of pembrolizumab (pembro) plus chemotherapy (chemo) improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR), with manageable safety, versus placebo (pbo) plus chemo for patients (pts) with advanced HER2-negative G/GEJ adenocarcinoma. Here, we report updated results from the subgroup analysis of pts enrolled in Asia after an additional 11 months of follow-up from the first interim analysis. Methods: Eligible pts aged ≥18 years with locally advanced unresectable or metastatic HER2-negative G/GEJ adenocarcinoma, an ECOG performance status (PS) of 0 or 1, and measurable disease per RECIST v1.1 were randomly assigned 1:1 to receive pembro 200 mg or pbo IV Q3W for ≤35 cycles; all pts received investigator’s choice of chemo (FP or CAPOX). The primary end point was OS. Secondary end points included PFS, ORR, and DOR per RECIST v1.1 by blinded independent central review, and safety. Efficacy end points were evaluated in all randomly assigned pts (intention to treat). Results: A total of 525 pts (263, pembro plus chemo; 262, pbo plus chemo) were enrolled in KEYNOTE-859 in Asia. The median time from randomization to database cutoff (August 22, 2023) was 39.2 months (range, 26.0-56.8). The median OS was 17.3 months (95% CI, 14.8-19.5) for pembro plus chemo versus 13.0 months (95% CI, 11.8-14.4) for pbo plus chemo (HR, 0.75; 95% CI, 0.62-0.91). The median PFS was 8.4 months (95% CI, 7.1-9.6) for pembro plus chemo versus 5.8 months (95% CI, 5.6-6.9) for pbo plus chemo (HR, 0.72; 95% CI, 0.58-0.89). The ORR was 61.2% (95% CI, 55.0-67.1; 36, complete response [CR]; 125, partial response [PR]) for pembro plus chemo and 48.5% (95% CI, 42.3-54.7; 24, CR; 103, PR;) for pbo plus chemo. The median DOR was 10.0 months (range, 1.2+ to 50.8+) for pembro plus chemo and 5.8 months (range, 1.3+ to 44.3+) for pbo plus chemo; 28.9% and 23.3% of pts, respectively, had a response lasting ≥24 months. Grade 3-5 treatment-related adverse events (AEs) occurred in 155 pts (59.2%) in the pembro plus chemo group and 119 pts (45.4%) in the pbo plus chemo group. Treatment-related AEs led to death in 1 pt (0.4%) in the pembro plus chemo group (unknown cause) and 2 pts (0.8%) in the pbo plus chemo group (cerebral hemorrhage and abnormal liver function). Immune-mediated AEs and infusion reactions occurred in 85 pts (32.4%) in the pembro plus chemo group and 35 pts (13.4%) in the pbo plus chemo group. Conclusions: The addition of pembro to chemo improved OS, PFS, and ORR in pts with advanced HER2-negative G/GEJ adenocarcinoma from Asia enrolled in KEYNOTE-859, with no new safety signals. These results further support first-line pembro plus chemo as a treatment option for this population. Clinical trial information: NCT03675737 .

Observation of minimal and maximal speed limits for few and many-body states

Nature Communications Zitian Zhu, Lei Gao, Zehang Bao et al. Feb 01, 2025 DOI: 10.1038/s41467-025-56451-3

Efficient Electrosynthesis of Hydrogen Peroxide Enabled by a Hierarchical Hollow RE–P–O (RE = Sm, La, Gd) Architecture with Open Channels

Advanced Materials Zhiwei Liu, Zhaowu Wang, Diandian Lv et al. Feb 01, 2025 DOI: 10.1002/adma.202311997

AbstractThe electrochemical two‐electron oxygen reduction reaction (2e− ORR) offers a sustainable pathway for the production of H2O2; however, the development of electrocatalysts with exceptional activity, selectivity, and long‐term stability remains a challenging task. Herein, a novel approach is presented to addressing this challenge by synthesizing hierarchical hollow SmPO4 nanospheres with open channels via a two‐step hydrothermal treatment. The produced compound demonstrates remarkable 2e− selectivity, exceeding 93% across a wide potential range of 0.0–0.6 V in 0.1 m KOH, with a peak of 96% at 0.45 V. When employed as the cathode in a flow cell, the synthesized SmPO4 exhibits impressive stability at 100 mA cm−2 for 12 h, consistently achieving a Faradaic efficiency above 90%. Using X‐ray absorption, in situ Raman and Fourier‐transform infrared spectroscopies, theoretical calculations, and post‐ORR assessments, it is found that this hollow compound possesses intrinsic open channels and is characterized by the optimal metal atomic spacing, and exceptional structural and compositional stabilities. These factors significantly enhance the thermodynamics, kinetics, and stability of the 2e− ORR process. Notably, the produced compound also exhibits outstanding 2e− ORR performance in neutral environments. Furthermore, this strategy can be extended to other hollow rare‐earth–P–O compounds, demonstrating excellent 2e− ORR performance under both neutral and alkaline conditions.

Toxicology and clinical protocol development of DUO-207: An ultrasmall nanomedicine co-delivering gemcitabine and paclitaxel for the treatment of metastatic pancreatic cancer.

Journal of Clinical Oncology Katherine Eichinger, Sam Rothstein, Victoria G. Manax et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.749

749 Background: The long-term survival rates for metastatic pancreatic cancer have remained stubbornly low for decades. Most pancreatic cancers have dense, fibrous stroma tissue surrounding their tumors, which contributes to tumor growth and acts as a barrier to many therapies. Nanomedicines have been developed for use in oncology to reduce toxicity and improve efficacy, but a majority are too large (&gt; 100nm) to effectively penetrate dense stroma. DUO-207 is a novel ultrasmall nanomedicine (~ 20nm) composed of copolymer-conjugated gemcitabine that encapsulates paclitaxel. Numerous preclinical efficacy models have demonstrated DUO-207’s ability to penetrate and accumulate in tumor tissue. Here we describe results from toxicology studies performed in canines that assisted in the design of a phase 1b clinical trial using the continual reassessment method (CRM). Methods: A single cycle, bridging toxicology study of DUO-207 with a recovery period was performed in canines. Animal equivalent doses of nano-albumin-bound paclitaxel (nAb-PTX) and gemcitabine were administered as the standard of care (SoC) comparator. Blood was analyzed for hematological toxicity, biomarkers of major organ toxicity, and drug toxicokinetics. Toxicology results from DUO-207 were then used in a statistical model to explore plausible scenarios for clinical dose escalation. Results: DUO-207 treated canines demonstrated improved clinical observations compared to SoC. As expected, hematologic toxicities occurred in a dose dependent fashion in the DUO-207 group but no hepato- or nephrotoxicity was noted. Based on these data, a phase 1b CRM design has been developed with 90% power to detect the maximum tolerated dose in key scenarios with an average sample size of 11 patients per group. Conclusions: In summary, DUO-207 is a novel, ultrasmall nanomedicine that can co-deliver paclitaxel and gemcitabine in a single intravenous infusion to treat stroma-rich cancers. DUO-207 demonstrated dose dependent hematological toxicities but improved clinical observations compared to SoC and lacked signals of renal and hepatoxicity. Toxicokinetic data from canines was used in a statistical model to determine patient numbers for phase 1b dosing using the CRM. Duo Oncology will conduct its clinical trial in 2025.

Risk factors for mortality and financial burdens in patients with colon cancer.

Journal of Clinical Oncology Zaid Zahid, Bugra Zengin, Mohammad Alqaisieh et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.300

300 Background: Colon cancer remains one of the most common cancers of the digestive system and continues to rank high among the leading causes of cancer-related deaths, despite the increased prevalence of screening. In this study, we aimed to investigate risk factors for mortality and health care costs in hospitalized patients diagnosed with colon cancer. Methods: Patients admitted to the hospital in 2019 and 2020 were identified using the Nationwide Inpatient Sample database and categorized into two groups based on the presence of colon cancer (with relevant ICD-10 codes). To account for confounding factors, multivariate regression analysis was applied to calculate mortality. Statistical analyses were conducted to assess mortality rates, length of stay, and hospital charges. Results: A total of 169,805 patients were admitted with a primary diagnosis of colon cancer, with a mean age of 67.6 years. The majority were White (69.9%), and 50.2% were male. Age over 60 (OR: 1.67, p &lt; 0.001) and sepsis (OR: 16.01, p &lt; 0.001) were associated with increased in-hospital mortality among colon cancer patients, while higher household income (76th to 100th percentile, OR: 0.71, p = 0.011) and treatment at an urban teaching facility (OR: 0.54, p &lt; 0.001) were linked to a lower risk of in-hospital mortality. Female gender (OR: 0.88, p = 0.080) and having inflammatory bowel disease (OR: 0.67, p = 0.055) did not significantly affect in-hospital mortality, nor did Black race (OR: 1.1, p = 0.348) or Hispanic race (OR: 1.15, p = 0.287) compared to White patients. Sepsis (+11.8 days, p&lt;0.001; +$192,699, p&lt; 0.001), age over 60 (+0.99 days, p&lt;0.001; +$6,134, p&lt;0.001), and care at urban teaching hospitals (+0.54 days, p&lt; 0.001; +$32,230, p&lt; 0.001) were associated with longer hospital stays and higher total charges. Conversely, female gender (-0.21 days, p=0.001; -$5,529, p&lt;0.001) and higher income (-0.69 days, p&lt;0.001; -$1,565, p=0.466) were linked to shorter hospital stays and lower total charges. Conclusions: Early recognition of sepsis in colon cancer patients could potentially reduce in-hospital mortality rates, as well as significantly decrease costs and length of stay. The higher mortality rates observed in patients with sepsis may be attributed to the immunocompromised state associated with cancer. Implementing targeted interventions to address the higher risks in older patients and those with sepsis could improve outcomes and reduce the overall burden of colon cancer-related hospitalizations. Impact of patient demographics, socioeconomic factors, and clinical conditions on mortality, length of hospital stay, and total hospital charges. Data Mortality Length of Hospital stay Total Charge Age&gt;60 1.67 (p&lt; 0.001) 0.99 days, p&lt;0.001 $6428, p&lt; 0.001 Race (Hispanic compared to White race) 1.15 (p=0.287) 0.38 days, p= 0.004 $14,127, p&lt;0.001 Race (Black compared to White race) 1.1 (p=0.348) 1.4 days, p&lt; 0.001 $5370, p=0.002 Female gender 0.88 (p=0.08) -0.21 days, p= 0.001 -$5529, p&lt; 0.001 High house hold income 0.71 (p= 0.011) -0.69 days, p&lt;0.001 -$1565, p= 0.466 Treatment at urban teaching facility 0.54 (p&lt;0.001 0.54 days, p&lt;0.001 $32230, p&lt; 0.001 Sepsis 16.01 (p&lt;0.001) 11.8 days, p&lt;0.001 $192699, p&lt; 0.001 IBD 1.05 (p=0.888) 0.67 days, p=0.055 $5348, p=0.293

Clinical-pathological characteristics, follow-up, and survival of patients with early-onset vs late-onset colorectal cancer: Institutional experience in Argentina.

Journal of Clinical Oncology Julian Maquieira, Anabella Botana, Ricardo Amorín et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.82

82 Background: The incidence of colorectal cancer (CRC) in young adults aged 50 or younger (Early Onset - EO) is increasing worldwide, while in patients over 50 years old (Late Onset - LO), it is declining. The objective is to compare the clinicopathological characteristics, time to diagnosis, and survival between Early Onset (EO) and Late Onset (LO) patients diagnosed with colorectal cancer (CRC). Methods: The sample was described using measures of central tendency and dispersion for continuous numerical variables and percentages for categorical variables. Clinical characteristics between Early Onset (EO) and Late Onset (LO) groups were compared using the Student’s t-test or Chi-square test. Kaplan-Meier curves and the Log-Rank Test were utilized to analyze mortality time. For multivariable analysis, a Cox regression model was applied. A p-value of less than 0.05 was considered statistically significant. The analysis was performed using RStudio. Results: A total of 460 patients were evaluated, with 343 diagnosed with colon adenocarcinoma and 117 with rectal cancer. Patients were grouped into two categories: the LO group with 408 (88.6%) patients and a mean age of 69.3 (8.60 SD) years, and the EO group with 52 (11.3%) patients and a mean age of 41.9 (6.23 SD) years. The EO group presented a higher percentage of patients with a PS of 0 compared to the LO group. In the EO group, there was a predominance of left-sided colon cancer (40.4% vs. 40.0%) and rectal cancer, especially in the middle and lower regions (30% vs. 18.8%), with disease diagnosed at stage III (26.9% vs. 26.5%) and IV (5.8% vs. 4.4%) compared to the LO group. Molecular testing for KRAS, NRAS, and BRAF mutations was more frequent in the EO group (19.2%, 3.8%, and 3.8%, respectively) compared to the LO group, as well as mismatch repair (MMR) status at 9.6% in the EO group vs. 6.9% in the LO group. The median time to diagnosis was 186 days in the LO group and 341 days in the EO group (p=0.21). Follow-up was 858 days in the LO group and 725 days in the EO group (p=0.18); while mortality was 200 (49.0%) in the LO group and 24 (46.2%) in the EO group, with a median survival of 1193 days for the LO group and 1414 days for the EO group, respectively (p=0.7). PS and stage were the most influential prognostic factors for mortality. Conclusions: In the comparison, the EO group showed a higher incidence of left-sided colon and rectal cancers, more advanced stages, better PS, and a greater number of molecular alterations, with a longer time to diagnosis and shorter follow-up. Although these differences were not statistically significant, they highlight the need to optimize prevention strategies and genetic counseling. Additional studies with a larger number of EO patients in real-life contexts are needed to generate more evidence that can improve clinical decision-making.

Effective in vivo binding energy landscape illustrates kinetic stability of RBPJ-DNA binding

Nature Communications Duyen Huynh, Philipp Hoffmeister, Tobias Friedrich et al. Feb 01, 2025 DOI: 10.1038/s41467-025-56515-4

Abstract Transcription factors (TFs) such as RBPJ in Notch signaling bind to specific DNA sequences to regulate transcription. How TF-DNA binding kinetics and cofactor interactions modulate gene regulation is mostly unknown. We determine the binding kinetics, transcriptional activity, and genome-wide chromatin occupation of RBPJ and mutant variants by live-cell single-molecule tracking, reporter assays, and ChIP-Seq. Importantly, the search time of RBPJ exceeds its residence time, indicating kinetic rather than thermodynamic binding stability. Impaired RBPJ-DNA binding as in Adams-Oliver-Syndrome affect both target site association and dissociation, while impaired cofactor binding mainly alters association and unspecific binding. Moreover, our data point to the possibility that cofactor binding contributes to target site specificity. Findings for other TFs comparable to RBPJ indicate that kinetic rather than thermodynamic DNA binding stability might prevail in vivo. We propose an effective in vivo binding energy landscape of TF-DNA interactions as instructive visualization of binding kinetics and mutation-induced changes.

Phase II study of modulation of sorafenib (SOR)-induced autophagy using hydroxychloroquine (HCQ) in advanced hepatocellular cancer (HCC).

Journal of Clinical Oncology Sukeshi Patel Arora, Jennifer L. Moseley, Luisa Marie Arellano et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.586

586 Background: SOR is the first systemic therapy approved for advanced HCC, but has shown only modest improvements in survival. Resistance to SOR in pre-clinical models has been attributed to autophagy induction. Autophagy inhibition with HCQ enhanced SOR-induced cell death and apoptosis in early pre-clinic and clinical studies. Data from the phase I study of SOR plus HCQ in advanced solid tumors at showed clinical safety and efficacy. Therefore, we conducted a prospective study to evaluate efficacy of SOR and HCQ in advanced HCC patients (pts) (NCT03037437) and report the final efficacy analysis. Methods: Prospective phase II study of SOR 400 mg po BID + HCQ 400 mg daily in pts with advanced HCC (CP A-B8 cirrhosis). Cohort 1: first-line SOR/HCQ. Cohort 2: add HCQ upon progressing on SOR. CP B pts started at 200 mg BID, with dose escalation as tolerated. Cycle = 4 weeks. Primary endpoint: mTTP. Secondary endpoints: mOS, objective response rate (ORR) by RECIST; AEs (NCI-CTCAEv3.0); PD analysis for markers of autophagy and immunity. Pts evaluable for efficacy if completed C1. Historically, the mTTP for patients treated with sorafenib is 5.5 mo (SHARP trial). We predicted the addition of HCQ will improve mTTP by 50% to 8.2 months. Results: N=33 completed C1. Median age 64.1 years SD 8.6 (46- 80). 88% Male; 58% Hispanics. ECOG 0-1: 100%. CP B cirrhosis: 35%. Etiology of cirrhosis: HCV 68%, ETOH 32%, NASH 11%. BCLC B 19%, C 81%. AFP&gt;400: 43%, PVT: 27%, extrahepatic/metastases: 68%, post-transplant: 27%. N=5 (14%) were in cohort 2 (prior SOR). Reason off study: PD (n=21), toxicity (n=5), lost to f/u (n=1), withdrew (n=3). mTTP is 8.0 months (95% CI: 4.0-19.0). mOS 10.0 months (95% CI: 6.0-22.0). ORR (CR+PR): 27%. Best response: CR n=1 (3%), PR n=8 (24%), SD n=14 (42%). 4+ cycles: n=19 (58%). AE on treatment: grade 1 (68%), 2 (24%), 3 (7%), 4 (0.6%), 5 (0.3%). No Gr 4/5 related to SOR or HCQ. Dose interruption (20%), dose reduction (10%). Conclusions: SOR/HCQ had a better mTTP (8.0 months) than historical control (mTTP=5.5 months, p=0.03), and the trial met its primary endpoint. SOR/HCQ ORR (27%) was higher than historically SOR alone (ORR 2%, SHARP) in pts with advanced HCC, predominantly BCLC C, with CP A and B cirrhosis (35%), and was tolerable. While immune checkpoint inhibitors (ICIs) are taking the forefront in advanced HCC, SOR/HCQ may still have a role in patients with CP B cirrhosis, post-transplant, or contraindications to ICIs. Further, analysis of predictive markers of response is ongoing. Clinical trial information: NCT03037437 .

Short interval circulating tumor DNA (ctDNA) kinetics as a predictor of tumor response in patients with gastrointestinal (GI) cancer receiving immune checkpoint inhibitor (ICI)-based treatment.

Journal of Clinical Oncology Sakti Chakrabarti, David L. Bajor, Melissa Amy Lumish et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.836

836 Background: Circulating tumor DNA (ctDNA) has a short half-life (&lt;2 hours) which may permit real-time monitoring of tumor status. This single-institution study aimed to assess the feasibility of rapid treatment response evaluation through serial short-interval ctDNA testing. Methods: Patients with gastrointestinal (GI) cancer undergoing immune checkpoint inhibitor (ICI)-based therapy were included. A personalized, tumor-informed ctDNA assay (Signatera, Natera, Inc.) was used in this study. We collected samples to measure the baseline ctDNA levels on cycle 1, day 1 (C1D1) of treatment or within 14 days prior to C1D1. A second ctDNA sample was obtained after 14-21 days depending on the cycle length of the treatment regimen employed (on cycle 2, day 1 [C2D1]). Changes in ctDNA levels between baseline and C2D1 were recorded, as well as the tumor response at the first radiographic assessment. Patients achieving partial response (PR) or better, or stable disease (SD) with tumor shrinkage supporting continuation of same treatment were considered responders. Results: The study cohort consisted of 14 patients aged 36-89 years (median age 66); 5 patients were female. Tumor types included advanced colorectal (n=5) and gastroesophageal (n=9) cancers. Treatments consisted of pembrolizumab alone (n=5), ICI + chemotherapy combinations (n=8), and regorafenib plus nivolumab (n=1). Baseline ctDNA levels were obtained on C1D1 in 9 patients, with the remaining 5 patients having baseline measurements within 14 days before C1D1. All patients had the second ctDNA level drawn on C2D1. The median interval between C1D1 and the first radiographic response assessment was 61 days (range, 45-84). A reduction in ctDNA levels by 50% or more (range: 66-100%) was observed in 9 patients (64%) after one cycle of treatment. All 9 patients were classified as responders at the time of first radiographic assessment: 7 with PR and 2 with SD but significant tumor shrinkage leading to continuation of the same treatment. In 3 patients (21%), ctDNA levels increased (range: 20-500%), correlating with progressive disease (PD) on first assessment scan. Two patients showed increased ctDNA levels of 82% and 22% after one cycle of treatment but achieved PR and SD, respectively. In both patients, however, the 3rd ctDNA level drawn before the first assessment scan dropped by &gt;90%. Overall, short-interval ctDNA kinetics correlated with treatment response in 12 of 14 patients (86%), with a binomial test p = 0.0065. Conclusions: Short-interval ctDNA kinetics demonstrates a strong correlation with radiographic tumor response and clinical benefit in GI cancer patients receiving ICI-based treatments, providing early signal of tumor response. This approach has the potential to guide treatment decisions if validated in larger prospective studies.